Opportunity Information: Apply for PAR 13 349
Apply for PAR 13 349
- The National Institutes of Health in the health income security and social services sector is offering a public funding opportunity titled "Sustained Release of Antivirals for Treatment and Prevention of HIV (SRATP) (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242 Mental Health Research Grants 93.855 Allergy and Infectious Diseases Research 93.856 Microbiology and Infectious Diseases Research 93.865 Child Health and Human Development Extramural Research.
- This funding opportunity was created on Sep 11, 2013 and posted on Sep 11, 2013.
- Applicants must submit their applications by Jan 7, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Private institutions of higher education County governments Others (see text field entitled Additional Information on Eligibility for clarification) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Special district governments Public housing authorities/Indian housing authorities Small businesses Public and State controlled institutions of higher education City or township governments Independent school districts State governments Native American tribal governments (Federally recognized).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Sustained Release of Antivirals for Treatment and Prevention of HIV (SRATP) (R01) funding opportunity (PAR-13-349) was a National Institutes of Health (NIH) discretionary grant program aimed at pushing forward sustained-release approaches for HIV therapeutics and prevention technologies. The core idea behind the announcement was to accelerate research that can keep effective levels of antiviral agents in the body for longer periods, reducing how often people need to take medication and helping address real-world challenges like adherence, access, stigma, and continuity of care. The FOA emphasized the long-term objective of developing practical, durable delivery strategies rather than short-acting formulations that require frequent dosing.
A central requirement in the announcement was the minimum duration of effect expected from proposed sustained-release products, depending on whether the application targeted treatment or prevention. For treatment-oriented strategies, the FOA sought platforms that could deliver at least one week of therapeutic efficacy, reflecting the need for longer-acting drug exposure to maintain viral suppression. For prevention-focused strategies (for example, pre-exposure prophylaxis approaches), the expectation was at least one month of protective efficacy, aligning with the concept that prevention products must maintain a reliable protective drug level over extended intervals to be useful outside tightly controlled clinical settings.
The FOA was broad in terms of the types of sustained-release platforms it encouraged. Applicants could propose oral sustained-release systems, long-acting injectable formulations, implants, or direct delivery methods aimed at HIV target mucosa. That last category reflects interest in approaches that concentrate antivirals at key sites of viral exposure or replication, potentially improving effectiveness while reducing systemic exposure. Overall, the program was positioned to support innovative formulation science, drug delivery engineering, and translational strategies that could plausibly move the field toward longer-duration HIV treatment and prevention options.
Administratively, this opportunity used the NIH R01 mechanism, meaning it was structured to support substantial research projects with a clear hypothesis-driven or milestone-driven plan and the expectation of generating robust preclinical or translational outcomes. It fell under health-related funding activity categories and was associated with multiple CFDA numbers, including 93.242 (Mental Health Research Grants), 93.855 (Allergy and Infectious Diseases Research), 93.856 (Microbiology and Infectious Diseases Research), and 93.865 (Child Health and Human Development Extramural Research). There was no cost-sharing or matching requirement, which typically lowers barriers to participation by not requiring applicants to contribute non-federal funds as a condition of the award.
Eligibility was expansive, which is consistent with NIH-wide goals of drawing in a wide range of scientific and community-facing capabilities. Eligible applicants included public and private institutions of higher education, nonprofit organizations (including both 501(c)(3) and non-501(c)(3) entities), for-profit organizations other than small businesses as well as small businesses, and many levels of government (state, county, city or township, special district governments, and certain housing authorities). The FOA also explicitly included tribal governments and tribal organizations, and it highlighted categories of institutions such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, tribally controlled colleges and universities (TCCUs), Alaska Native and Native Hawaiian serving institutions, and Asian American and Native American Pacific Islander serving institutions (AANAPISIs). Importantly, non-U.S. entities were eligible to apply, foreign institutions were allowed, and foreign components of U.S. organizations could participate as defined in NIH policy, reflecting the global nature of HIV research and the international relevance of prevention and treatment delivery technologies.
In terms of timing and status, the FOA was posted and created on September 11, 2013, with an original and final closing date of January 7, 2016, and it was archived on February 7, 2016. The sponsoring agency was the NIH, and the full announcement was hosted through the NIH grants guide under the provided link. For technical access issues, the contact point listed was the NIH Office of Extramural Research (OER) webmaster email.
Taken together, PAR-13-349 was designed to fund research that could realistically transform how HIV antivirals are delivered by extending dosing intervals through sustained-release technologies, with clear minimum performance expectations (one week for treatment; one month for prevention) and openness to multiple delivery routes and a wide range of applicant organizations, including domestic and international institutions.
Frequently Asked Questions (FAQs)
What is PAR-13-349 (SRATP) and what was it designed to fund?
PAR-13-349, titled "The Sustained Release of Antivirals for Treatment and Prevention of HIV (SRATP) (R01)," was a National Institutes of Health (NIH) discretionary grant opportunity intended to advance sustained-release approaches for HIV therapeutics and HIV prevention technologies. The focus was on research that could maintain effective antiviral levels in the body for longer periods to reduce dosing frequency and address real-world barriers such as adherence, access, stigma, and continuity of care.
What was the core goal of the SRATP funding opportunity?
The core goal was to accelerate research into practical, durable antiviral delivery strategies that extend drug exposure over meaningful timeframes, rather than short-acting formulations that require frequent dosing.
What minimum duration of effect was required for treatment-focused applications?
For treatment-oriented strategies, the funding opportunity expected proposed sustained-release products to deliver at least one week of therapeutic efficacy.
What minimum duration of effect was required for prevention-focused applications?
For prevention-focused strategies (for example, pre-exposure prophylaxis approaches), the expectation was at least one month of protective efficacy.
Why did the FOA set different duration expectations for treatment versus prevention?
Based on the announcement, treatment strategies were aligned with maintaining longer-acting exposure to support viral suppression (minimum one week), while prevention products were expected to sustain reliable protective levels over longer intervals (minimum one month) to be useful outside tightly controlled clinical settings.
What types of sustained-release platforms were encouraged?
The announcement encouraged a broad range of sustained-release approaches, including oral sustained-release systems, long-acting injectable formulations, implants, and direct delivery methods aimed at HIV target mucosa.
What does "direct delivery to HIV target mucosa" mean in the context of this FOA?
Within the scope described, it refers to approaches designed to deliver antivirals directly to mucosal sites relevant to HIV exposure or replication, potentially concentrating drug where it is most needed and possibly reducing systemic exposure.
What grant mechanism was used for this opportunity?
This opportunity used the NIH R01 mechanism, which is typically used to support substantial research projects with a clear hypothesis-driven or milestone-driven plan and an expectation of generating robust preclinical or translational outcomes.
Was cost sharing or matching required?
No. The opportunity stated there was no cost-sharing or matching requirement, meaning applicants were not required to contribute non-federal funds as a condition of the award.
Who was eligible to apply?
Eligibility was expansive. Eligible applicants included public and private institutions of higher education; nonprofit organizations (including both 501(c)(3) and non-501(c)(3) entities); for-profit organizations (including small businesses and other than small businesses); and multiple levels of government (including state, county, city or township, special district governments, and certain housing authorities). Tribal governments and tribal organizations were also explicitly included.
Were minority-serving institutions explicitly included in eligibility?
Yes. The announcement highlighted eligibility for institutions such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, tribally controlled colleges and universities (TCCUs), Alaska Native and Native Hawaiian serving institutions, and Asian American and Native American Pacific Islander serving institutions (AANAPISIs).
Could non-U.S. organizations apply?
Yes. Non-U.S. entities were eligible to apply. Foreign institutions were allowed, and foreign components of U.S. organizations could participate as defined in NIH policy.
What research areas or disciplines did SRATP aim to support?
Based on the description provided, the program was positioned to support innovative formulation science, drug delivery engineering, and translational strategies that could move the field toward longer-duration HIV treatment and prevention options.
Which federal agency sponsored the opportunity?
The sponsoring agency was the National Institutes of Health (NIH).
Which CFDA numbers were associated with this opportunity?
The announcement was associated with multiple CFDA numbers: 93.242 (Mental Health Research Grants), 93.855 (Allergy and Infectious Diseases Research), 93.856 (Microbiology and Infectious Diseases Research), and 93.865 (Child Health and Human Development Extramural Research).
When was the FOA created and when did it close?
The FOA was posted and created on September 11, 2013. It had an original and final closing date of January 7, 2016.
Is this funding opportunity still active?
No. The opportunity was archived on February 7, 2016.
Where was the full announcement hosted?
The full announcement was hosted through the NIH grants guide under the provided link referenced in the opportunity description.
Who was listed as the contact for technical access issues?
For technical access issues, the contact point listed was the NIH Office of Extramural Research (OER) webmaster email.
What kinds of real-world challenges did the FOA aim to address through sustained-release approaches?
The description emphasized reducing how often people need to take medication and helping address adherence, access, stigma, and continuity of care by enabling longer-lasting antiviral drug levels.
Browse more opportunities from the same category: Health Income Security and Social Services
Next opportunity: NIH Support for Conferences and Scientific Meetings (Parent R13/U13)
Previous opportunity: NIDCR Small Grant Program for New Investigators (R03)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 13 349
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 13 349) also looked into and applied for these:
| Funding Opportunity |
|---|
| Enhancing the Capacity for Biomedical Research on Tuberculosis for HIV infected Mothers and Children in India (R01) Apply for RFA HD 14 025 Funding Number: RFA HD 14 025 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $350,000 |
| Developmental Origins of Health and Disease (DOHaD) Epigenetic Modification in Gametogenesis and Transgenerational Inheritance (R01) Apply for PAR 13 385 Funding Number: PAR 13 385 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $250,000 |
| Female Contraceptive Development Program (U01) Apply for RFA HD 14 024 Funding Number: RFA HD 14 024 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $250,000 |
| Discovery of Molecular Targets for Pregnancy Related/Induced Diseases and Development of Therapeutics to Prevent/Treat These Diseases (SBIR) (R43/R44) Apply for RFA HD 14 031 Funding Number: RFA HD 14 031 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Discovery of Molecular Targets for Pregnancy Related/Induced Diseases and Development of Therapeutics to Prevent/Treat These Diseases (R01) Apply for PAR 13 389 Funding Number: PAR 13 389 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Discovery of Molecular Targets for Pregnancy Related/Induced Diseases and Development of Therapeutics to Prevent/Treat These Diseases (STTR) (R41/R42) Apply for RFA HD 14 032 Funding Number: RFA HD 14 032 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Centers for Collaborative Research in Fragile X (U54) Apply for RFA HD 14 033 Funding Number: RFA HD 14 033 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $1,300,000 |
| Juvenile Protective Factors and Their Effects on Aging (R03) Apply for PAR 14 022 Funding Number: PAR 14 022 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $200,000 |
| U.S South Africa Program for Collaborative Biomedical Research (U01) Apply for RFA AI 14 018 Funding Number: RFA AI 14 018 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $225,000 |
| Data Sharing for Demographic Research Infrastructure Program (U24) Apply for RFA HD 14 015 Funding Number: RFA HD 14 015 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Intellectual and Developmental Disabilities Research Centers 2014 (U54) Apply for RFA HD 14 012 Funding Number: RFA HD 14 012 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $1,300,000 |
| Population Dynamics Centers Research Infrastructure (P2C) Apply for RFA HD 14 016 Funding Number: RFA HD 14 016 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Data Coordinating Center for the Collaborative Pediatric Critical Care Research Network (U01) Apply for RFA HD 14 020 Funding Number: RFA HD 14 020 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Collaborative Pediatric Critical Care Research Network (UG1) Apply for RFA HD 14 022 Funding Number: RFA HD 14 022 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Sustained Release for Antiretroviral Treatment or Prevention (SRATP) of HIV Infection (UM1) Apply for RFA AI 14 008 Funding Number: RFA AI 14 008 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Isolation, Purification, and Synthesis of Human Milk Oligosaccharides with Antimicrobial Activity (R43) Apply for RFA HD 15 008 Funding Number: RFA HD 15 008 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $150,000 |
| Isolation, Purification, and Synthesis of Human Milk Oligosaccharides with Antimicrobial Activity (R41) Apply for RFA HD 15 007 Funding Number: RFA HD 15 007 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $150,000 |
| Male Contraceptive Development Program (U01) Apply for RFA HD 14 034 Funding Number: RFA HD 14 034 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $200,000 |
| Global Omics Approaches Targeting Adverse Pregnancy and Neonatal Outcomes Utilizing Existing Cohorts (R01) Apply for PAR 14 264 Funding Number: PAR 14 264 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Peripheral Blood Biomarkers of Chronic Traumatic Brain Injury in Human Subjects SBIR Direct Phase II (R44) Apply for RFA HD 15 012 Funding Number: RFA HD 15 012 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $750,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 13 349", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.